Trade Names:Brovana- Solution for inhalation 15 mcg
Relaxes bronchial smooth muscles.
C max is 4.3 pg/mL and occurs approximately 0.5 h after administration.
In vitro plasma protein binding is 52% to 65%.
Metabolized primarily by direct conjugation (glucuronidation) and secondarily by demethylation (CYP2D6 and, to a lesser degree, CYP2C19).
After 14 days, 67% is recovered in urine and 22% in feces.
Long-term maintenance treatment of bronchoconstriction in COPD, including bronchitis and emphysema.
History of hypersensitivity to arformoterol, racemic formoterol, or any component of the product.
Inhalation 15 mcg twice daily (morning and evening) by nebulization (max, 30 mcg/day).
Store in the protective foil pouch under refrigeration at 36° to 46°F. Protect from light and excessive heat. Once foil pouch is opened, use contents of vial immediately. Discard any vial if solution is not colorless. Unopened foil pouch also may be stored at room temperature (68° to 77°F) for up to 6 wk.
Arformoterol sympathomimetic effects may be potentiated.Beta-blockers
Effects of both agents may be inhibited.Diuretics, methylxanthines (eg, aminophylline, theophylline), steroids
May potentiate the hypokalemic effect of arformoterol.MAOIs, tricyclic antidepressants, drugs known to prolong the QTc interval
Arformoterol may potentiate these agents, increasing the risk of cardiac arrhythmias.Non-potassium-sparing diuretics (eg, loop or thiazide diuretics)
ECG changes and/or hypokalemia may be worsened by arformoterol.
None well documented.
Arteriosclerosis, atrial flutter, AV block, CHF, heart block, inverted T-wave, MI, QT interval prolongation, supraventricular tachycardia (less than 2%).
Agitation, cerebral infarct, circumoral paresthesia, hypokinesia, paralysis, somnolence, tremor (less than 2%).
Rash (4%); dry skin, herpes simplex, herpes zoster, skin discoloration, skin hypertrophy (less than 2%).
Abnormal vision, glaucoma (less than 2%).
Diarrhea (6%); constipation, gastritis, melena, oral moniliasis, periodontal abscess, rectal hemorrhage (less than 2%).
Breast neoplasm, calcium crystalluria, cystitis, glycosuria, hematuria, increased prostate-specific antigen, kidney calculus, nocturia, pyuria, urinary tract disorder, urine abnormality (less than 2%).
Decreased glucose tolerance, dehydration, edema, gout, hyperglycemia, hyperlipemia, hypoglycemia, hypokalemia (less than 2%).
Back pain (6%); leg cramps (4%); arthralgia, arthritis, bone disorder, neck rigidity, pelvic pain, rheumatoid arthritis, tendinous contracture (less than 2%).
Sinusitis (5%); dyspnea (4%); lung disorder, primarily pulmonary or chest congestion (2%); lung carcinoma, respiratory disorder, voice alteration (less than 2%).
Pain (8%); chest pain (7%); flu syndrome, peripheral edema (3%); abscess, allergic reaction, digitalis intoxication, fever, hernia, neoplasm, retroperitoneal hemorrhage (less than 2%).
Long-acting beta 2 -adrenergic agonists may increase the risk of asthma-related death.
Category C .
Safety and efficacy not established.
Use of arformoterol in these conditions is inappropriate.
Arformoterol is not indicated for treating acute symptoms of COPD.
Can cause clinically important CV effects; therefore, use with caution in patients with CV disorders, especially coronary insufficiency, cardiac arrhythmia, and hypertension.
If paradoxical bronchospasm occurs, discontinue arformoterol and institute alternative therapy.
Immediate hypersensitivity reactions may occur.
Angina, arrhythmias, cardiac arrest, death, dizziness, dry mouth, fatigue, headache, hyperglycemia, hypertension, hypokalemia, hypotension, insomnia, malaise, metabolic acidosis, muscle cramp, nausea, nervousness, palpitation, tachycardia, tremor.
Copyright © 2009 Wolters Kluwer Health.